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BACKGROUND: A series of controlled changes including proliferation, secretion and menstrual shedding occur in
the human endometrium during every normal menstrual cycle. Macrophage migration inhibitory factor (MIF), a
multifunctional cytokine with numerous proinflammatory, immunomodulatory and angiogenic properties, appears
to be expressed in the human endometrium and to follow a regulated cycle phase-dependent expression, but the
mechanisms underlying endometrial MIF expression remain to be fully elucidated. METHODS AND RESULTS:
Results from enzyme-linked immunosorbent assay (ELISA) demonstrated a significant dose- and time-dependent
increase in MIF secretion by human endometrial cells in response to tumour necrosis factor-alpha (TNF-) (0.1–100
ng/ml). This increase was also observed at the mRNA level as shown by reverse transcription (RT)–PCR. Curcumin
(108 mol/l), a known nuclear factor (NF)-B inhibitor, inhibited the TNF--induced pIB phosphorylation as shown
by western blotting, NF-B translocation into the nucleus as shown by electrophoretic mobility shift assay, and MIF
synthesis and secretion as measured by ELISA and RT–PCR. The expression of a dominant-negative NF-B inhibi-
tor (IB) significantly decreased the TNF--induced MIF promoter activity as analysed by transient cell transfec-
tion. CONCLUSIONS: These results indicate clearly that TNF- up-regulates the expression of MIF in endometrial
stromal cells. This took place possibly through NF-B activation, and may play an important role in the physiology of
the human endometrium.
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Introduction
Human endometrium undergoes a series of controlled changes
including proliferation, secretion and menstrual shedding during
every normal menstrual cycle. These dynamic processes require
a network of hormonal, growth and immunoinflammatory fac-
tors in which cytokines locally produced within the endometrial
tissue play a crucial role (Tabibzadeh, 1996; 1998; Lebovic
et al., 2000; von Wolff et al., 2000; Bigonnesse et al., 2001;
Boucher et al., 2001; Critchley et al., 2001). Of particular inter-
est is the role that appears to be played by tumour necrosis factor-
alpha (TNF-α) in human endometrial physiology.
TNF-α was first identified as a cytokine secreted by endo-
toxin-activated macrophages that induced the necrosis of tumours
(Carswell et al., 1975). TNF-α is now known as a pluripotent cell
mediator and angiogenic cytokine that promotes the production
of other cytokines in various cells (Feldmann and Maini, 1999).
The human endometrium is characterized by a variety of cell
types, including fibroblasts, immune cells, vascular cells and
epithelial cells, all of which express TNF-α (Hunt et al., 1992;
Philippeaux and Piguet, 1993; Tabibzadeh et al., 1995; Chegini
et al., 1999; von Wolff et al., 1999; Bergqvist et al., 2000; 2001).
Despite discrepancies in the cycle expression patterns, these stud-
ies suggest a local role for TNF-α in a variety of normal endome-
trial functions. Increased expression of this cytokine was shown
to cause pathophysiological effects reflected by its involvement
in implantation failure (Hazout, 1995), abortion (Giacomucci
et al., 1994) and endometriosis (Zhang et al., 1993).
Our previous studies identified macrophage migration inhib-
itory factor (MIF) as a potent mitogenic factor for human
endothelial cells released by ectopic endometrial cells (Yang
et al., 2000) in women with endometriosis (Kats et al., 2002b).
Subsequent studies from our laboratory showed a cycle phase-
dependent expression of MIF during the menstrual cycle, with
a particular increase occurring in the late secretory phase, sug-
gesting a tight regulation and perhaps different roles for this
factor in the reparative, reproductive and inflammatory-like
processes that occur in human endometrium during the normal
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menstrual cycle (Kats et al., 2005). MIF, one of the first
described cytokines, was identified for its ability to inhibit
macrophage migration within the inflammatory sites (Bloom
and Bennett, 1970; David, 1966). More recent studies have
shown, however, that MIF is rather a multifunctional cytokine/
hormone endowed with a multitude of proinflammatory,
immunomodulatory, angiogenic and tissue remodelling effects
(Metz and Bucala, 1997; Nishihira, 1998; Calandra and Roger,
2003; Nishihira et al., 2003). Accordingly, we believe that MIF
may in different ways influence human endometrial tissue
functions and be involved in its normal cyclic changes.
The mechanisms underlying MIF expression in the human
endometrial tissue remain unknown. Herein we report that
TNF-α had a direct stimulatory effect on MIF expression by
human endometrial stromal cells. Cell treatment with TNF-α
caused a significant increase in MIF protein secretion and
mRNA synthesis, which appeared to be likely mediated by the
activation of the nuclear transcription factor NF-κB. Interac-
tion between TNF-α and MIF, owing to the properties of these
two major and multifunctional cytokines, may play a consider-
able role in the physiology of the human endemetrium.
Materials and methods
Subjects and tissue handling
Endometrial biopsies were obtained during laparoscopy for tubal liga-
tion from eight normal fertile women who had not received hormonal
or anti-inflammatory therapy for at least 3 months before surgery
(mean age ± SD, 30.71 ± 4.03 years). Four women were in the prolif-
erative phase of the menstrual and four in the secretory phase. Written
informed consent was obtained from these women under a study pro-
tocol approved by the Ethical Committee on Human Research at
Laval University, Quebec, Canada. Biopsies were obtained by aspira-
tion with the use of a Pipelle (Unimar Inc., Prodimed, Neuilly-En-
Tchelle, France), immediately placed at 4°C in sterile Hank’s bal-
anced salt solution containing 100 U/ml penicillin, 100 μg/ml
streptamycin and 0.25 μg/ml amphotericin B (Invitrogen Life Tech-
nologies, Burlington, ON, Canada) and transported to the laboratory.
Cell culture and stimulation
Endometrial stromal cells were obtained and characterized according to
our previously described procedure (Boucher et al., 2000). Cells were
subcultured to eliminate contamination by macrophages or other leuko-
cytes and used between passages 3 and 5. Extensive characterization of
cell cultures prepared using this protocol previously confirmed >95%
purity with cells retaining cytoskeletal markers of their endometrial stro-
mal origin. For enzyme-linked immunosorbent assay (ELISA) and
reverse transcription (RT)–PCR studies, endometrial cells were plated in
12-well plates in Dulbecco’s minimal essential medium F-12 medium,
supplied with 10% fetal bovine serum (FBS), 5 μg/ml insulin, 5 μg/ml
transferrin and 1% antibiotics–antimycotics. Medium was changed every
48 h. When cells proliferated to confluence, the culture medium was
replaced overnight with serum-free medium, then with serum-free and
phenol red-free medium containing various concentrations of TNF-α (0–
100 ng/ml) (R & D systems, Minneapolis, MN, USA) for different time
periods (0–24 h). In some cultures, curcumin (10−8 mol/l) (Sigma Chemi-
cal Co., St Louis, MO, USA), an extract from plant known for inhibiting
NF-κB (D’Acquisto et al., 2002; Ghosh and Karin, 2002) was added 1 h
before TNF-α. The culture supernatants were collected for MIF ELISA,
whereas cells were collected for mRNA or nuclear protein extraction.
Immunocytofluorescence
Endometrial stromal cells were plated on chamber slides (Nalge Nunc
International, Naperville, IL, USA). At confluence, cells were incu-
bated overnight with serum-free medium, and then with TNF-α at
1 ng/ml for 6 h. Cells were then fixed in formaldehyde [3.5% v/v in
phosphate buffered saline (PBS)] for 15 min at room temperature,
rinsed in PBS–0.01% Tween 20, incubated with a goat anti-human
MIF antibody [0.66 mg/ml in PBS/0.2% bovine serum albumin (BSA)/
0.01% Tween 20] (R & D Systems) for 90 min at room temperature,
rinsed in PBS–0.01% Tween 20, incubated with fluoresceine isothio-
cyanate (FITC)-conjugated anti-goat antibody (1/50 dilution in PBS-
BSA-Tween) (Jackson ImmunoResearch Laboratories, West Grove,
PA, USA), rinsed in PBS–0.01% Tween 20 and mounted in Mowiol
containing 10% para-phenylenediamine (Sigma). Cells incubated with-
out the primary antibody or with goat immunoglobulins (Sigma) at the
same concentration as the primary antibody were included as negative
controls. Slides were observed under a microscope equipped for fluo-
rescence (Leica mikroskopie und systeme GmbH, Model DMRB;
Postfach, Wetzlar, Germany) and photographed.
ELISA
MIF ELISA was performed using a mouse monoclonal anti-human-MIF
antibody (R & D Systems) as a capture antibody, a rabbit polyclonal
anti-human-MIF antibody for detection with an alkaline phosphatase-
conjugated goat anti-rabbit antibody and para-nitrophenyl phosphate
(Sigma) as substrate (Calandra et al., 1995). The optical density was
measured at 405 nm and MIF concentrations were extrapolated from a
standard curve using recombinant human MIF. The sensitivity limit of
the assay was 300 pg/ml, with intra- and inter-assay coefficients of
variation <4%.
RT–PCR
Briefly, following appropriate treatment with TNF-α, cells were
washed with ice-cold PBS and extraction of total RNA was performed
with Trizol reagent according to the manufacturer’s instructions
(Invitrogen). RNA was reverse transcribed in the presence of random
primers, and the resulting cDNA was amplified with oligonucleotide
primers specific to human MIF (amplimer size 255 bp) and to human
glyceraldehyde phosphate dehydrogenase (GAPDH) used as internal
control (amplimer size 240 bp). The PCR reaction products were then
separated on 1.2% agarose gel by electrophoresis for qualitative ana-
lysis of mRNA expression as described previously (Kats et al., 2002b).
Quantitative real-time PCRs were carried out in an ABI 7000
Thermal Cycler (Applied Biosystems). Each standard PCR reaction
contains 2 ml of RT product, 0.5 ml of each primer (final concentration,
5 pmol/l), 12.5 ml SYBR Green PCR Master Mix consisting of Taq
DNA polymerase reaction buffer, dNTP mix, SYBR green I, MgCl2
and Taq DNA polymerase. Following a 10 min denaturation at 95°C,
the reactions were cycled 40 times with a 15 s denaturation at 95°C
and a 60 s annealing at 59 or 60°C for MIF and GAPDH, respectively.
MIF primers (forward, 5′-GCCCGGACAGGGTCTACA-3′; reverse,
5′-CTTAGGCGAAGGTGGAGTTGTT-3′; amplimer size 125 bp)
(Boeuf et al., 2005), and GAPDH primers (forward, 5′-CAGGGCT-
GCTTTTAACTCTGG-3′; reverse, 5′-TGGGTGGAATCATATT-
GGAACA-3′; amplimer size 102 bp) designed with Primer Express™,
version 2.0 (Applied Biosystems), span intron–exon boundaries to
avoid amplification of genomic DNA, and were selected so as to have
compatible Tm values (59–61°C). Quantitation of MIF mRNA was
performed using a relative quantitation method. For each experimen-
tal sample, MIF mRNA levels were normalized to GAPDH mRNA
levels. After each run, melting curve analysis (55–95°C) was per-
formed to verify the specificity of the PCR. All samples were tested in
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duplicate, and each run included no-template and no-reverse tran-
scription controls.
Western blotting
Briefly, 80 μl lysis buffer (50 mmol/l Tris–HCl, 125 mmol/l NaCl,
0.1% Nonidet-P40, 5 mmol/l ethylenediamine tetraacetic acid,
50 mmol/l NaF, 0.1% phenylmethylsulfonylfluoride and protease
inhibitors) was used to extract cytoproteins after collecting cells with
cold PBS supplied with phosphorylation inhibitors. Proteins (20 μg)
were electrophoretically separated using 10% SDS–PAGE, then trans-
ferred onto polyvinylidene difluoride membranes (Millipore Corp.,
Bedford, MA, USA) overnight at 4°C. After incubation with anti-human
p-IκB (Active Motif, Carlsbad, CA, USA) in 0.1% Tween 20–PBS for
1.5 h at room temperature, membranes were incubated with horserad-
ish peroxidase (HRP)-labelled anti-mouse IgGs for 1 h, and a chemi-
luminescence kit was used for detection following the manufacturer’s
instructions (Roche, IN, USA). Membranes were stripped and reblot-
ted with a monoclonal antibody specific to tubulin (Sigma) (1:50 000
dilution in Tween 20–PBS) used as an internal control for protein
loading and transfer.
Extraction of nuclear proteins and EMSA
Nuclear proteins were extracted using a nuclear extract kit according
to the manufacturer’s instructions (Active Motif) and protein concen-
tration was determined using the Bio-Rad DC Protein assay kit (Bio-
Rad Laboratories Ltd, Mississauga, ON, Canada). Nuclear extracts
were stored at –80°C until use.
DNA binding of NF-κB was examined using the consensus oligonu-
cleotide of NF-κB (5′-AGT TGA GGG GAC TTT CCC AGG C-3′).
The oligonucleotide was end-labelled with (32P)γ-ATP (Amersham
Pharmacia Biotech) using T4 polynucleotide kinase (Promega,
Madison, WI, USA). The labelled probe was purified using a Probe-
Quant G-50 micro-column (Amersham Biosciences, Baie d’Urfe, QC,
Canada) (3000 r.p.m., 1 min) and recovered in Tris–EDTA buffer pH
8.0. Binding reactions included 5 μg of nuclear proteins in incubation
buffer containing 50 mmol/l Tris–HCl pH 7.5, 250 mmol/l NaCl,
2.5 mmol/l dithiothreitol, 2.5 mmol/l EDTA, 5 mmol/l MgCl2, 0.25 mg/ml
poly(dI–dC)poly(dI–dC) and 20% glycerol. After 10 min, the labelled
oligonucleotide (4 × 105 c.p.m.) was added and the mixture was incu-
bated for 20 min at room temperature in a final volume of 10 μl. When
indicated, controls for specific or non-specific competitions were per-
formed using unlabelled NF-κB which was added 20 min before the
incubation with the labelled oligonucleotide. Immediately after binding,
the nucleoprotein–oligonucleotide complexes were separated from
unbound oligonucleotide by electrophoresis on a non-denaturing 4%
acrylamide gel at 100 V for 4 h using 0.5 mol/l Tris–borate–EDTA
(TBE) buffer. The gel was then dried and exposed overnight at –80°C to
×-ray films (BioMax; Eastman Kodak, Rochester, NY, USA).
Transfections and luciferase assays
Transfections were performed in triplicate in 24-well plates using Plus
and LipofectAMINE Reagents (Invitrogen) as described by the manu-
facturer. Cells were transiently co-transfected with 0.5 μg of human
MIF promoter construct in the pGL3 luciferase reporter vector (pGL3-
MIF) and 1 μg of human IκB dominant-negative cDNA (S32A/S36A)
in the pUSE vector (pUSE-IκB) (Upstate, Charlottesville, VA, USA),
or with the appropriate control vectors pGL3 and pUSE. Cells were
then washed with PBS and incubated in the culture medium contain-
ing 10% FBS overnight before they were stimulated with 1 ng/ml
TNF-α for 24 h. Cell extracts were assayed for firefly and renilla luci-
ferase activities using the dual luciferase reporter assay system
(Promega) as instructed by the manufacturer.
Statistical analysis
Data were expressed as mean ± SEM. An unpaired t-test was used
for comparing two means, and one-way ANOVA followed by the
Dunnett’s test was performed for multiple comparisons using Graph-
Pad Software, Prism 3.0 (GraphPad Software, San Diego, CA, USA).
Differences were considered as statistically significant whenever a
P-value <0.05 occurred.
Results
Analysis of MIF expression in endometrial stromal cells in
response to TNF-α was first examined by immunocytofluores-
cence using anti-MIF antibody. Only a weak staining was
observed in cells incubated with the culture medium alone with-
out stimulus (Figure 1A). However, cell incubation with TNF-α
(1 ng/ml) for 24 h markedly increased MIF immunostaining (Fig-
ure 1B). Staining was virtually absent in cells incubated with goat
IgGs instead of anti-MIF antibody or with anti-MIF antibody pre-
absorbed with an excess rhMIF (2 μg/ml) (data not shown).
MIF secretion by endometrial stromal cells in response to
TNF-α was then quantified by ELISA. As shown in Figure 2,
TNF-α induced a dose- and time-dependent increase in MIF con-
centration in the culture medium. There was no significant
increase in MIF secretion in response to TNF-α after 2 h of stim-
ulation. Treatment with 0.1 ng/ml resulted in a progressive
increase in MIF secretion, although with no statistical signifi-
cance. MIF secretion was statistically significant after 6, 12 and
24 h of stimulation with 1 and 10 ng/ml TNF-α (P < 0.05), and
appeared to reach a plateau after 6 h of treatment, whereas higher
TNF-α concentration (100 ng/ml) induced a statistically signific-
ant increase in MIF secretion after 24 h of stimulation (P < 0.05).
The effects of TNF-α on MIF gene expression in endome-
trial stromal cells were further analysed by RT–PCR. As
shown in Figure 3, endometrial stromal cells express detectable
levels of MIF mRNA in culture without stimuli. However, add-
ing TNF-α (0–100 ng/ml) to the culture medium for 24 h con-
siderably increased MIF mRNA levels in a dose-dependent
manner. Quantitative analysis of MIF mRNA expression using
real-time PCR confirmed these data and further showed a sig-
nificant increase in MIF mRNA levels in endometrial stromal
cells in response to 1 (P < 0.01) and 10 (P < 0.05) ng/ml TNF-α.
Figure 1. TNF-α increased MIF expression as detected by immuno-
cytofluorescence. Human endometrial stromal cell cultured to conflu-
ence in chamber were incubated for 24 h in culture medium without
stimuli (A) or with 1 ng/ml TNF-α (B). Cells were fixed and MIF
protein was visualized with goat anti-hMIF and FITC-anti-goat IgGs.
Scale bar = 30 μm.
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Transcription factor NF-κB plays a major role in the regula-
tion of the expression of multiple genes that control the
immune system, growth and inflammation (Makarov et al.,
1997). NF-κB appeared to play an important role in mediating
TNF-α effects in a variety of cell types (Makarov et al., 1997).
However, it is still unknown whether NF-κB is involved
in MIF gene transcription. Our data showed that curcumin
(10−8 mol/l), an NF-κB inhibitor (Xu et al., 1997; Bharti et al.,
2003), significantly decreased the ability of TNF-α to induce
MIF protein secretion (P < 0.05) and mRNA synthesis (P <
0.01) (Figure 4). Analysis of nuclear proteins showed that
TNF-α induced expression of the functional p50 component of
NF-κB in endometrial stromal cells, as indicated by binding of
radiolabelled p50-specific NF-κB oligonucleotide and by
super-shifting of this complex with an antibody specific to NF-
κB p50. The TNF-α-induced NF-κB p50 band was reduced or
eliminated by curcumin (10−8 mol/l) or an excess of unlabelled
oligonucleotide (Figure 5). Phosphorylation of the NF-κB
inhibitor, IκB, inactivates IκB, and allows NF-κB to translo-
cate into the cell nucleus where it triggers synthesis of inflam-
matory cytokines (Makarov et al., 1997). As shown in Figure 6,
pIκB was increased after exposure to TNF-α (1 ng/ml), and the
increase was inhibited by curcumin (10−8 mol/l) as detected by
western blot.
To further determine whether NF-κB can be involved in
MIF gene transcription, the transcriptional activity of the MIF
promoter–luciferase construct was evaluated after co-transfection
with the pUSE-IκB dominant-negative construct in the presence
and absence of TNF-α. The pUSE-IκB dominant-negative vec-
tor expresses a mutated non-phosphorylatable, non-degradable
IκB. The results showed that the activity of the MIF promoter
Figure 2. TNF-α induced a dose- and time-dependent increase in
MIF protein secretion in the culture medium as analysed by ELISA.
The bars represent means ± SEM; *P < 0.05 versus control (culture
medium without stimuli for each incubation time), as analysed by the
Dunnett’s test.
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Figure 3. TNF-α increased MIF mRNA steady-state levels in cul-
tured human endometrial stromal cells. Cells were treated with TNF-α
(0, 0.1, 1, 10 and 100 ng/ml) for 24 h. Total RNA was extracted and
reverse transcribed, then MIF and GAPDH (internal control) cDNAs
were amplified by PCR as described in Material and methods.
(A) Analysis of amplified cDNAs by electrophoresis and ethidium
bromide staining; (B) quantitative real-time PCR analysis. MIF
mRNA levels were expressed as MIF to GAPDH mRNA ratio. The
bars represent means ± SEM; *P < 0.05, **P < 0.01 versus control
(culture medium without stimuli), as analysed by the Dunnett’s test.
Figure 4. Curcumin suppressed TNF-α-induced increase in MIF
expression in endometrial stromal cells. Confluent cultures of
endometrial stromal cells were preincubated for 1 h with or without
curcumin (10 nmol/l); TNF-α (1 ng/ml) was then added and the cells
were incubated for further 24 h. (A) MIF concentration in the culture
supernatant as measured by ELISA; (B) MIF mRNA levels as evalu-
ated by real-time PCR. The bars represent means ± SEM. *Signifi-
cant stimulation of MIF secretion and mRNA synthesis by TNF-α as
analysed by the unpaired t-test (P < 0.05); †P < 0.05 and ††P < 0.01,
significant inhibition of TNF-α-induced MIF secretion and mRNA
synthesis in the presence of curcumin, as analysed by the unpaired t-test.
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was significantly stimulated with TNF-α (P < 0.05). Furthermore,
cell co-transfection with the pUSE-IκB dominant-negative
vector resulted in a significant inhibition of the TNF-α-induced
MIF promoter activity (Figure 7).
Discussion
These results indicate, for the first time, that TNF-α up-regu-
lates MIF gene expression and protein synthesis in human
endometrial stromal cells and that this effect is mediated by
activation of NF-κB. In quiescent cells, NF-κB is bound to
IκB in the cytoplasm. Upon stimulation by various agents
such as TNF-α, IκB undergoes phosphorylation to form p-IκB,
which subsequently undergoes ubiquitylation and degrada-
tion. This process allows NF-κB to enter the nucleus, where it
activates cytokines, adhesion molecules, cyclooxygenase and
other target genes (Makarov et al., 1997). Several compounds
are now used as NF-κB inhibitors with different levels of
effects. Our data showed that curcumin depressed the ability
of TNF-α to increase MIF secretion and inhibited pIκB phos-
phorylation and NF-κB translocation into the nucleus. Fur-
thermore, co-transfection of endometrial cells with MIF
promoter and IκB dominant-negative vectors resulted in a sig-
nificant inhibition of the TNF-α-induced activation of the MIF
promoter. These data suggest that TNF-α activates MIF gene
transcription in human endometrial stromal cells, and provide
further evidence on the ability of TNF-α to up-regulate MIF
expression via NF-κB.
It is now quite well-known that TNF-α is a pluripotent cell
mediator having proinflammatory, growth/apoptotic and ang-
iogenic effects and a wide spectrum of cell targets (Feldmann
and Maini, 1999). TNF-α has been detected in various repro-
ductive organs including the ovaries (Roby et al., 1990), the
oviduct (Hunt, 1993), the endometrium and preimplantation
embryos (Zolti et al., 1991; Hunt et al., 1992; Philippeaux and
Piguet, 1993; Sharkey et al., 1995; Tabibzadeh et al., 1995;
Figure 5. TNF-α induced nuclear translocation of NF-κB as ana-
lysed by electrophoretic mobility shift assay (EMSA). Confluent cell
cultures were exposed for 6 h to medium alone, medium with TNF-α
(1 ng/ml) or medium with TNF-α (1 ng/ml) following 1 h preincuba-
tion with curcumin (10−8 mol/l). Nuclear protein extracts (5 μg) were
incubated with radiolabelled NF-κB oligonucleotide. The resulting
complexes were separated on 5% non-denaturing polyacrylamide gel.
To test for specificity of NF-κB binding, supershift analysis with
antibody against the p50 subunit of NF-κB (NF-κB-Ab) and competi-
tion experiments with unlabelled oligonucleotide were conducted.
Figure 6. TNF-α induced IκB phosphorylation in human endome-
trial stromal cells, as detected by western blot. Confluent cell cultures
were exposed to medium without stimuli, 1 ng/ml TNF-α or 1 ng/ml
TNF-α for 15 min following 1 h preincubation with 10−8 mol/l curcu-
min. Twenty micrograms of total proteins were separated by electro-
phoresis on a 10% gradient polyacrylamide gel and immunoblotted
using mouse monoclonal anti-pIκB antibodies and HRP-anti-mouse
IgGs (pIκBa, 43 kDa). Tubulin levels are shown to demonstrate equal
protein loading.
Figure 7. IκB dominant-negative inhibited TNF-α-induced MIF
promoter activity. Human endometrial stromal cells were transiently
co-transfected with pGL3-MIF and pUSE-IκB, or with the appropri-
ate control vectors pGL3 and pUSE. The transfected cells were then
incubated for 24 h with and without TNF-α (1 ng/ml) before being
harvested. Cell lysates were analysed for firefly and renilla luciferase
activities as described in Materials and methods. Data were expressed
as precentage of control which represents MIF promoter activity
without co-expression of dominant-negative IκB and stimulation with
TNF-α (cells co-transfected with pGL3-MIF and the pUSE vector
and incubated with the culture medium). The bars represent means ±
SEM. *Significant increase in MIF promoter activity in response to
TNF-α as compared to the culture medium (P < 0.05); †significant
decrease in the TNF-α-induced MIF promoter activity following co-
transfection with dominant-negative IκB (P < 0.05), as analysed by
the unpaired t-test.
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Chegini et al., 1999; von Wolff et al., 1999), thus implicating
TNF-α in reproduction.
Several studies have shown the menstrual cycle-dependent
production of TNF-α in the human endometrium, its expres-
sion in different cell types and the presence of TNF receptors
(Hunt et al., 1992; Philippeaux and Piguet, 1993; Tabibzadeh
et al., 1995; Chegini et al., 1999; von Wolff et al., 1999).
Despite discrepancies in the cyclic expression patterns, these
studies suggest a local role for TNF-α in a variety of endome-
trial functions. This is not surprising, since the human
endometrium represents one of the most dynamic tissues dur-
ing the reproductive age, and cytokines appear to have a cru-
cial role in the regulation of the cyclic events of cell
proliferation, remodelling, angiogenesis, apoptosis/necrosis,
bleeding and menstrual shedding occurring in this tissue
(Tabibzadeh, 1996; 1998; Lebovic et al., 2000; von Wolff et al.,
2000; Bigonnesse et al., 2001; Boucher et al., 2001; Critchley
et al., 2001). Thus, our study showing an up-regulation of MIF
expression by TNF-α in human endometrial cells identifies one
of the potential mechanisms underlying MIF expression in the
human endometrium, and points to a plausible interaction
between these two multifunctional cytokines the local expres-
sion and biological properties of which are of particular rele-
vance for the physiology of a tissue like the human
endometrium.
MIF was first reported in 1932 and was described as a
cytokine produced by T lymphocytes that inhibited the random
migration of microphages during delayed hypersensitivity
(David, 1966; Bloom and Bennett, 1970). It is now well docu-
mented that MIF is a major multifunctional proinflammatory
cytokine that activates a number of immunocompetent cells
(Metz and Bucala, 1997; Calandra and Roger, 2003; Nishihira
et al., 2003) and overrides the anti-inflammatory effects of glu-
cocorticoids (Calandra and Bucala, 1997; Kitaichi et al., 2000).
New evidence, however, showed a wider spectrum of action
for MIF and an involvement in angiogenesis and tissue remod-
elling (Metz and Bucala, 1997; Nishihira, 1998; Calandra and
Roger, 2003; Nishihira et al., 2003). For instance, MIF was
shown to promote directly endothelial cell proliferation in vitro
(Chesney et al., 1999; Ogawa et al., 2000; Yang et al., 2000), to
stimulate angiogenesis in vivo (Chesney et al., 1999; Nishihira
et al., 2003) and to induce the synthesis and the secretion of
matrix metalloproteinases in different cell types (Meyer-Siegler,
2000; Onodera et al., 2000), including endometrial cells accord-
ing to our recent data (A.Akoum and M.J.Therriault, unpub-
lished data). Accordingly, it is quite possible that local induction
and production of MIF may contribute to active tissue remod-
elling and angiogenesis that take place in the endometrial
tissue and are required for the tissue’s growth and regeneration,
as well as to the inflammatory-like process of leukocyte inva-
sion and menstrual breakdown occurring at the end of the cycle
in the absence of implantation (Critchley et al., 2001).
The findings of the present study may have a particular rele-
vance for the understanding of endometriosis, a common gyne-
cological disorder where an endometrial-like tissue creates
lesions outside the uterus (Sampson, 1927; Taylor, 2003).
Endometriosis is recognized as an inflammatory-like disorder; a
chronic immunoinflammatory process has often been described
in the peritoneal cavity of endometriosis patients (Halme et al.,
1987; Taylor, 2003; Wu and Ho, 2003). Peritoneal fluid from
patients with endometriosis was shown to contain high levels of
leukocytes, particularly macrophages, and inflammatory
cytokines. These cytokines could then contribute to the develop-
ment of peritoneal endometriosis by promoting endometrial cell
adhesion, invasion and proliferation (Hammond et al., 1993;
Zhang et al., 1993; Barcz et al., 2000; Wu and Ho, 2003).
Several studies have shown a significant role of TNF-α in
endometriosis pathophysiology. Elevated concentrations of
TNF-α were found in the peritoneal fluid of women with
endometriosis (Rana et al., 1996; Barcz et al., 2000; Iwabe et al.,
2000; Bedaiwy et al., 2002; Bullimore, 2003; Darai et al., 2003).
TNF-α appeared to stimulate metalloproteinase expression (Sillem
et al., 2001), to favour cell adhesion to mesothelial cells (Zhang
et al., 1993) and to play a considerable role in endometriosis-
associated immunoinflammatory changes (Sakamoto et al.,
2003). Interestingly, TNF-α appeared to enhance eutopic and
ectopic endometrial cell growth (Iwabe et al., 2000; Braun et al.,
2002; Sakamoto et al., 2003), but failed to do so in endometrial
cells of controls without endometriosis (Braun et al., 2002).
This is suggestive of an endometriosis-related intrinsic difference
in endometrial cell responsiveness to TNF-α, and in keeping
with our previous data showing an increased secretion of
monocyte chemotactic protein-1 (MCP-1) in endometrial epi-
thelial cells of women with endometriosis exposed to TNF-α in
vitro (Akoum et al., 1995). The effect of TNF-α on MIF secre-
tion by eutopic as well as ectopic endometrial cells of women
with endometriosis remains to be elucidated, and it is still to be
determined whether these cells had a modified responsiveness
to TNF-α with regard to MIF secretion. Nevertheless, our data
showing a marked stimulatory effect of TNF-α on endometrial
stromal cell secretion of MIF, suggest that peritoneal fluid
TNF-α may interact with retrograde endometrial tissue and
activate NF-κB, thereby stimulating MIF secretion and exacer-
bating inflammation. This is all the more plausible since our
previous studies showed a marked increase in MIF expression
in ectopic endometrial tissue and the peritoneal fluid of
endometriosis patients and a relationship with the disease stage
(Kats et al., 2002a; b).
In conclusion, our study provides for the first time evidence
that TNF-α increases MIF expression in human endometrial
stromal cells and that such an effect is mediated by NF-κB.
This, owing to the properties of these two major and multifunc-
tional cytokines, may play an important role in the cyclic
changes occurring in the human endometrial tissue and poten-
tially contribute to endometriosis pathophysiolgy.
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